Julie Avolio
Overview
Explore the profile of Julie Avolio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cuevas-Ocana S, Laselva O, Avolio J, Nenna R
Breathe (Sheff)
. 2020 Dec;
16(2):200016.
PMID: 33304402
https://bit.ly/3aRafQF.
12.
Cao H, Ouyang H, Laselva O, Bartlett C, Zhou Z, Duan C, et al.
Eur Respir J
. 2020 May;
56(5).
PMID: 32457197
Cystic fibrosis (CF) is a genetic disorder affecting multiple organs, including the pancreas, hepatobiliary system and reproductive organs; however, lung disease is responsible for the majority of morbidity and mortality....
13.
Grasemann H, Klingel M, Avolio J, Prentice C, Gonska T, Tullis E, et al.
Eur Respir J
. 2019 Oct;
55(1).
PMID: 31601715
No abstract available.
14.
Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, et al.
PLoS Genet
. 2019 Feb;
15(2):e1008007.
PMID: 30807572
Cystic Fibrosis (CF) exhibits morbidity in several organs, including progressive lung disease in all patients and intestinal obstruction at birth (meconium ileus) in ~15%. Individuals with the same causal CFTR...
15.
Ooi C, Syed S, Rossi L, Garg M, Needham B, Avolio J, et al.
Sci Rep
. 2018 Dec;
8(1):17834.
PMID: 30546102
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Next to progressive airway disease, CF is also associated with intestinal inflammation and dysbiosis....
16.
Eckford P, McCormack J, Munsie L, He G, Stanojevic S, Pereira S, et al.
J Cyst Fibros
. 2018 Apr;
18(1):35-43.
PMID: 29685812
Background: Therapies targeting certain CFTR mutants have been approved, yet variations in clinical response highlight the need for in-vitro and genetic tools that predict patient-specific clinical outcomes. Toward this goal,...
17.
Ahmadi S, Bozoky Z, Di Paola M, Xia S, Li C, Wong A, et al.
NPJ Genom Med
. 2017 Jun;
2:12.
PMID: 28649446
Pulmonary disease is the major cause of morbidity and mortality in patients with cystic fibrosis, a disease caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. Heterogeneity...
18.
Kane M, Gonska T, Jensen R, Avolio J, Klingel M, Stanojevic S, et al.
Thorax
. 2016 Mar;
71(5):476-7.
PMID: 26944510
No abstract available.
19.
Cao H, Ouyang H, Ip W, Du K, Duan W, Avolio J, et al.
Mol Ther Methods Clin Dev
. 2016 Jan;
2:15034.
PMID: 26730394
Cystic fibrosis (CF) results from mutations in the CF transmembrane conductance regulator (CFTR) gene, which codes for a chloride/bicarbonate channel in the apical epithelial membranes. CFTR dysfunction results in a...
20.
Grasemann H, Gonska T, Avolio J, Klingel M, Tullis E, Ratjen F
J Cyst Fibros
. 2015 Jul;
14(6):727-32.
PMID: 26168933
Unlabelled: Airways of patients with cystic fibrosis are deficient for nitric oxide. Low nitric oxide in cystic fibrosis has been shown to be associated with poor pulmonary function and risk...